Items where authors include "Syndikus, I"

Article

James, ND, Liu, W, Pirrie, S et al. (19 more authors) (2023) TUXEDO: a phase I/II trial of cetuximab with chemoradiotherapy in muscle‐invasive bladder cancer. BJU International, 131 (1). pp. 63-72. ISSN 1464-4096

Huddart, R, Hafeez, S, Lewis, R et al. (20 more authors) (2021) Clinical Outcomes of a Randomized Trial of Adaptive Plan-of-the-Day Treatment in Patients Receiving Ultra-hypofractionated Weekly Radiation Therapy for Bladder Cancer. International Journal of Radiation: Oncology - Biology - Physics, 110 (2). pp. 412-424. ISSN 0360-3016

Syndikus, I, Cruickshank, C, Staffurth, J et al. (11 more authors) (2020) PIVOTALboost: A phase III randomised controlled trial of prostate and pelvis versus prostate alone radiotherapy with or without prostate boost (CRUK/16/018). Clinical and Translational Radiation Oncology, 25. pp. 22-28. ISSN 2405-6308

Zaorsky, NG, Yu, JB, McBride, SM et al. (11 more authors) (2020) Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19. Advances in Radiation Oncology, 5 (4). pp. 659-665. ISSN 2452-1094

Mateo, J, Porta, N, Bianchini, D et al. (38 more authors) (2020) Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. The Lancet Oncology, 21 (1). pp. 162-174. ISSN 1470-2045

Conference or Workshop Item

Huddart, R, Hafeez, S, Omar, A et al. (22 more authors) (2021) Acute toxicity of hypo- and conventionally-fractionated radiosensitised bladder radiotherapy. In: ESTRO 2021, 28-31 Aug 2021, Madrid, Spain & Online.

Huddart, RA, Lewis, R, Griffin, C et al. (17 more authors) (2020) Patterns of use of chemotherapy with radiotherapy in the treatment of muscle-invasive bladder cancer: Data from the RAIDER randomized trial of adaptive radiotherapy. In: 2020 Genitourinary Cancers Symposium, 13-15 Feb 2020, San Francisco, CA, USA.

Cruickshank, C, Mayles, H, Naismith, O et al. (8 more authors) (2019) Successful collaboration between a Clinical Trial Unit (CTU) and the National Radiotherapy Trials Quality Assurance (RTTQA) Group to expedite opening a complex phase III trial (PIVOTALboost). In: 5th International Clinical Trials Methodology Conference (ICTMC 2019), 06-09 Oct 2019, Brighton, UK.

Proceedings Paper

Hunt, A, Chan, A, Delacroix, L et al. (21 more authors) (2019) Establishing international variation in target delineation using MRI for bladder radiotherapy. In: Radiotherapy and Oncology. ESTRO 38, 26-30 Apr 2019, Milan, Italy. Elsevier BV , S857-S858.

Huddart, R, Henry, A orcid.org/0000-0002-5379-6618, Staffurth, J et al. (16 more authors) (2018) OC-0058: Clinical outcomes of the first rct of adaptive radiotherapy in bladder cancer (HYBRID CRUK/12/055). In: Radiotherapy and Oncology. ESTRO 37, 20-24 Apr 2018, Barcelona, Spain. Elsevier , S25-S26.